SPIDR: small-molecule peptide-influenced drug repurposing

BackgroundConventional de novo drug design is costly and time consuming, making it accessible to only the best resourced research organizations. An emergent approach to new drug development is drug repurposing, in which compounds that have already gone through some level of clinical testing are examined for efficacy against diseases divergent than their original application. Repurposing of existing drugs circumvents the time and considerable cost of early stages of drug development, and can be accelerated by using software to screen existing chemical databases to identify suitable drug candidates.ResultsSmall-molecule Peptide-Influenced Drug Repurposing (SPIDR) was developed to identify small molecule drugs that target a specific receptor by exploring the conformational binding space of peptide ligands. SPIDR was tested using the potent and selective 16-amino acid peptide α-conotoxin MII ligand and the α3β2-nicotinic acetylcholine receptor (nAChR) isoform. SPIDR incorporates a genetic algorithm-based, heuristic search procedure, which was used to explore the ligand binding domain of the α3β2-nAChR isoform using a library consisting of 640,000 α-conotoxin MII peptide analogs. The peptides that exhibited the highest affinity for α3β2-nAChR were used as models for a small-molecule structure similarity search of the PubChem Compound database. SPIDR incorporates the SimSearcher utility, which generates shape distribution signatures of molecules and employs multi-level K-means clustering to insure fast database queries. SPIDR identified non-peptide drugs with estimated binding affinities nearly double that of the native α-conotoxin MII peptide.ConclusionsSPIDR has been generalized and integrated into DockoMatic v 2.1. This software contains an intuitive graphical interface for peptide mutant screening workflow and facilitates mapping, clustering, and searching of local molecular databases, making DockoMatic a valuable tool for researchers in drug design and repurposing.

[1]  A. Hofman,et al.  Smoking and Parkinson's disease: Systematic review of prospective studies , 2004, Movement disorders : official journal of the Movement Disorder Society.

[2]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[3]  Stephen T. C. Wong,et al.  Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. , 2014, Drug discovery today.

[4]  D. Yoshikami,et al.  A New -Conotoxin Which Targets 32 Nicotinic Acetylcholine Receptors (*) , 1996, The Journal of Biological Chemistry.

[5]  Peter J. Fleming,et al.  An Overview of Evolutionary Algorithms in Multiobjective Optimization , 1995, Evolutionary Computation.

[6]  Reed B. Jacob,et al.  DockoMatic - Automated Peptide Analog Creation for High Throughput Virtual Screening , 2011 .

[7]  Jie Li,et al.  SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug–target interactions and drug repositioning , 2016, Briefings Bioinform..

[8]  D. Morens,et al.  Epidemiologic observations on Parkinson's disease , 1996, Neurology.

[9]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[10]  Chuang Liu,et al.  Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..

[11]  R. W. Hansen,et al.  Journal of Health Economics , 2016 .

[12]  Michael J. Marks,et al.  Analogs of α-conotoxin MII are selective for α6-containing nicotinic acetylcholine receptors , 2004 .

[13]  Igor V. Tetko,et al.  ToxAlerts: A Web Server of Structural Alerts for Toxic Chemicals and Compounds with Potential Adverse Reactions , 2012, J. Chem. Inf. Model..

[14]  E K Perry,et al.  Nicotinic receptor subtypes in human brain related to aging and dementia. , 2001, Alcohol.

[15]  Jinbo Xu,et al.  Rapid Protein Side-Chain Packing via Tree Decomposition , 2005, RECOMB.

[16]  The Uniprot Consortium,et al.  UniProt: a hub for protein information , 2014, Nucleic Acids Res..

[17]  Xiaolin Cheng,et al.  Targeted Molecular Dynamics Study of C-Loop Closure and Channel Gating in Nicotinic Receptors , 2006, PLoS Comput. Biol..

[18]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[19]  C. Shaw.  Venom-based medicines: Advancing drug discovery with reptile and amphibian venom peptides , 2009 .

[20]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[21]  Gerard Pujadas,et al.  BDT: an easy-to-use front-end application for automation of massive docking tasks and complex docking strategies with AutoDock , 2006, Bioinform..

[22]  David S. Goodsell,et al.  A semiempirical free energy force field with charge‐based desolvation , 2007, J. Comput. Chem..

[23]  L. Miranda,et al.  Progress and challenges in the optimization of toxin peptides for development as pain therapeutics. , 2017, Current opinion in chemical biology.

[24]  Antony J. Williams,et al.  ChemSpider:: An Online Chemical Information Resource , 2010 .

[25]  Timothy L. Andersen,et al.  GAMPMS: Genetic algorithm managed peptide mutant screening , 2015, J. Comput. Chem..

[26]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[27]  Reed B. Jacob,et al.  The M-superfamily of conotoxins: a review , 2009, Cellular and Molecular Life Sciences.

[28]  A. C. Collins,et al.  Pharmacology of α-Conotoxin MII-Sensitive Subtypes of Nicotinic Acetylcholine Receptors Isolated by Breeding of Null Mutant Mice , 2007, Molecular Pharmacology.

[29]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[30]  Antonino Lauria,et al.  The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New Advances and Perspectives. , 2016, Current topics in medicinal chemistry.

[31]  Jie Shen,et al.  admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties , 2012, J. Chem. Inf. Model..

[32]  Timothy L. Andersen,et al.  Genetic Algorithm Managed Peptide Mutant Screening: Optimizing Peptide Ligands for Targeted Receptor Binding , 2016, J. Chem. Inf. Model..

[33]  P. Alewood,et al.  Structure-activity studies on alpha-conotoxins. , 2011, Current pharmaceutical design.

[34]  Owen M. McDougal,et al.  Acetylcholine Promotes Binding of α‐Conotoxin MII at α3β2 Nicotinic Acetylcholine Receptors , 2014, Chembiochem : a European journal of chemical biology.

[35]  M. Picciotto,et al.  Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. , 2008, Frontiers in bioscience : a journal and virtual library.

[36]  Evan Bolton,et al.  Fast 3D shape screening of large chemical databases through alignment-recycling , 2007, Chemistry Central journal.

[37]  T. Sixma,et al.  Crystal Structure of Acetylcholine-binding Protein from Bulinus truncatus Reveals the Conserved Structural Scaffold and Sites of Variation in Nicotinic Acetylcholine Receptors* , 2005, Journal of Biological Chemistry.

[38]  P. Taylor,et al.  Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations , 2005, The EMBO journal.

[39]  F. Joseph McClernon,et al.  Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization , 2006, Psychopharmacology.

[40]  J. Lindstrom,et al.  Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors. , 2004, Molecular pharmacology.

[41]  P. DeotarseP.,et al.  Drug Repositioning: A Review , 2015 .

[42]  Tudor I. Oprea,et al.  Drug Repurposing: Far Beyond New Targets for Old Drugs , 2012, The AAPS Journal.

[43]  Igor V. Tetko,et al.  Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information , 2011, J. Comput. Aided Mol. Des..

[44]  Gang Fu,et al.  PubChem Substance and Compound databases , 2015, Nucleic Acids Res..

[45]  Bonnie Berger,et al.  Fast and accurate algorithms for protein side-chain packing , 2006, JACM.

[46]  Bernard Chazelle,et al.  Shape distributions , 2002, TOGS.

[47]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[48]  B. Ueberheide,et al.  Venom peptides as therapeutics: advances, challenges and the future of venom-peptide discovery , 2017, Expert review of proteomics.

[49]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[50]  A. C. Collins,et al.  125I-alpha-conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain. , 2000, Molecular pharmacology.

[51]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[52]  Marcel H. Schulz,et al.  Research in Computational Molecular Biology , 2018, Lecture Notes in Computer Science.

[53]  N. Unwin,et al.  Refined structure of the nicotinic acetylcholine receptor at 4A resolution. , 2005, Journal of molecular biology.

[54]  Zengjian Hu,et al.  Windock: Structure‐based drug discovery on windows‐based PCs , 2007, J. Comput. Chem..

[55]  Olivier Michielin,et al.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.

[56]  Reed B. Jacob,et al.  Dockomatic - automated ligand creation and docking , 2010, BMC Research Notes.